By the PharmaTradz BD Team. Published October 2026.
Immediate-release (IR) medicines release their active ingredient straight away after they are swallowed. Modified-release medicines are designed to change that timing. Extended-release (ER, also written XR, XL, SR or CR) products release the drug slowly over many hours, so it can be taken less often. Delayed-release (DR) products, usually enteric-coated, hold the drug back until the tablet has passed the stomach. "Controlled release" is mostly a brand or marketing term for an extended-release design. The letters after a medicine's name are not decoration: they describe a different product, with different data behind it.
For buyers and importers, mixing these up is one of the easier ways to order the wrong product, or to register a product that will not be accepted as equivalent.
The release types at a glance
| Type | Common labels | What it does | Typical examples |
|---|---|---|---|
| Immediate release | IR, or no suffix | Dissolves and releases the drug soon after swallowing | Most standard tablets and capsules |
| Extended release | ER, XR, XL, SR, CR, LA, PR | Releases the drug slowly, keeping levels steadier for longer and allowing once- or twice-daily dosing | Metformin ER, nifedipine ER, tamsulosin (sold as an MR or prolonged-release product) |
| Delayed release | DR, EC (enteric-coated) | A coating that survives stomach acid and dissolves in the intestine, to protect the drug from acid or the stomach from the drug | Pantoprazole, enteric-coated aspirin, gastro-resistant mesalazine tablets |
| Orally disintegrating | ODT, MD | Dissolves on the tongue without water; release is otherwise immediate | Ondansetron ODT |
Pharmacopoeias treat "modified release" as the umbrella term, with extended release and delayed release as its two main forms. Suffixes such as SR, CR and LA are used by manufacturers, and the same letters can mean slightly different things for different brands, which is why the product information always matters more than the label.
How modified release is achieved
There are several technical routes, and the choice affects cost, manufacturing complexity and which manufacturers can make the product. Matrix tablets embed the drug in a polymer that swells or erodes slowly. Coated pellets or beads, filled into capsules, release the drug through a membrane. Osmotic systems push the drug out through a laser-drilled hole at a steady rate. Enteric coatings use polymers that only dissolve above a certain pH. Each needs specialised equipment and, above all, careful control of dissolution, the test that shows how quickly the drug comes out of the dosage form.
Why it matters to buyers and importers
IR and ER are not interchangeable. A 500 mg immediate-release tablet and a 500 mg extended-release tablet contain the same amount of drug but behave quite differently in the body. Your order, your dossier and your tender response must all name the release type, not just the molecule and strength.
The data behind a modified-release generic is heavier. Regulators usually expect more extensive bioequivalence work for modified-release products than for immediate-release ones, often including studies under fed as well as fasting conditions, and a detailed comparison of dissolution profiles. That is one reason fewer manufacturers offer ER and DR versions, and why dossiers for them are worth more.
Dissolution is the specification to watch. For an ER or DR product, the dissolution test is what proves the product behaves as designed. Check that the supplier's specification and Certificate of Analysis report it in full; our explainer on reading a Certificate of Analysis covers what to look for.
Climate and packaging matter more. Some modified-release coatings and matrices are sensitive to humidity. For hot, humid markets, ask for stability data at zone IVb conditions and confirm the pack, often an alu-alu blister, protects the product.
Patients must not crush or split most ER and DR tablets unless the product information says they can, because doing so can release the whole dose at once or destroy the coating. Labels and patient leaflets in the destination language need to say this clearly.
Related explainers
For the active ingredient itself, see what an API is; for the difference between the ingredient and the finished medicine, drug substance versus drug product. If you are looking for a manufacturer, our page on tablet contract manufacturing explains what to check in a partner.
More explainers
Related terms buyers ask about: batch versus lot numbers, fixed-dose combinations (FDCs), small molecules versus biologics and what an excipient is. For supplier documents, see what a DMF is and how to read a Certificate of Analysis.
How PharmaTradz can help
Tell us the molecule, strength and release type you need, and the market it is for. We match you with manufacturers who make that exact dosage form and share their document status, including dissolution and bioequivalence data where it exists, before you commit. Send us an RFQ to get started.
Frequently Asked Questions(FAQs)
What is the difference between ER and DR?
Extended release (ER) releases the drug slowly over many hours so it can be taken less often. Delayed release (DR), usually an enteric coating, holds the drug back until the tablet has passed the stomach, then releases it.
Is CR the same as ER?
Usually, yes. "Controlled release" is mostly a brand or marketing term for an extended-release design. Always check the product information, because suffixes are not standardised between manufacturers.
What does IR mean on a medicine?
IR stands for immediate release: the tablet or capsule releases its drug soon after it is swallowed. Most standard tablets are immediate release even when no suffix is shown.
Can an ER tablet be replaced with an IR tablet of the same strength?
No. They contain the same amount of drug but release it very differently, so they are different products with different dosing. Substitution should only follow the prescriber's and regulator's rules.
Why are modified-release generics harder to register?
Regulators usually ask for more extensive bioequivalence data for modified-release products, often including fed and fasting studies, plus detailed dissolution comparisons with the reference product.
